Sanofi, Health2Sync ink pact for digital solution to diabetes management
Taipei: Health2Sync, a digital health startup, specializing in diabetes management, has entered into a partnership with Sanofi, a biopharmaceutical company focused on providing different healthcare solutions including diabetes.
Through this partnership, Health2Sync becomes one of the Sanofi Diabetes Digital Healthcare Ecosystem partners, the two companies aim to apply the digital solution provided by Health2Sync in 300 clinics and hospitals nationwide certified by Taiwan Diabetes Shared Care Network over the next 3 years to improve diabetes care and management locally, as well as to accelerate digital adoption and transformation for clinics and hospitals.
According to an analysis in 2019 Diabetes Atlas: achievements and challenges in diabetes care in Taiwan, published by the Taiwan Association of Diabetes Educators, over 60% of diabetes patients in Taiwan cannot reach HbA1c <7%, and the insulinization rate in Taiwan is 12%, which is realtively low compared with America and European countries. At present, there are more than 2.2 million diabetes patients in Taiwan, which results in a huge and costly burden on the healthcare system. Moreover, patients are frightened to seek necessary care amid COVID-19. How to leverage digital tools to help healthcare professionals provide a better long-term care and management to patients has become an opportunity for this partnership between Sanofi and Health2Sync.
"Chronic disease management now requires a more holistic and integrated approach involving all stakeholders, from prevention to treatment and care; while doctors are increasingly looking for innovative ways of managing disease and therapeutic options," said Anthony Jones, Head of Virtual Healthcare, Hong Kong & Taiwan at Sanofi.
As part of the partnership, Health2Sync will provide patient management software for healthcare professionals and a mobile app for patients in 300 Sanofi-contracted clinics and hospitals, to realize an integrated and digitized diabetes management. The ultimate goal is to improve patients' understanding of insulin, increase glucose control and raise the insulinization rate in Taiwan. Health2Sync's analytics platform will assist doctors in real-time with decision making, treatment planning, and generating insights based on the health data collected with patient consent. The solution will help identify patients suited for insulin initiation and facilitate insulin titration for healthcare providers.
"Sanofi is not just a pharma company that provides medications. Sanofi is a healthcare company that combines medications and integrated care solutions to optimize the patient journey. The collaboration is just a beginning, and Sanofi aims to keep bringing digital therapeutics solutions to reach a comprehensive Diabetes Digital Healthcare Ecosystem," added Shelley Chan, Head of Diabetes, Hong Kong & Taiwan at Sanofi.
"Health2Sync's solution brings a new definition to the chronic disease care loop, thanks to seamless data collection, real-time analytics, and ultimately, timely medical intervention. With our focus on digital therapeutics, there couldn't have been a better market than Taiwan as a start, thanks to the local initiatives and robust medical practice. Our commitment to both empower patients and lessen the burden of the cost of complications arising from diabetes will be further exemplified in this partnership," said Ed Deng, Co-founder & CEO of Health2Sync.
Read also: Sanofi Dupixent gets USFDA Breakthrough Therapy designation to treat eosinophilic esophagitis
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.